These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 21955466)
21. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. Vigan R; Neil SJ J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465 [TBL] [Abstract][Full Text] [Related]
22. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. Sauter D; Unterweger D; Vogl M; Usmani SM; Heigele A; Kluge SF; Hermkes E; Moll M; Barker E; Peeters M; Learn GH; Bibollet-Ruche F; Fritz JV; Fackler OT; Hahn BH; Kirchhoff F PLoS Pathog; 2012 Dec; 8(12):e1003093. PubMed ID: 23308067 [TBL] [Abstract][Full Text] [Related]
23. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail. Lucas TM; Janaka SK; Stephens EB; Johnson MC PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757 [TBL] [Abstract][Full Text] [Related]
24. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin. Fritz JV; Tibroni N; Keppler OT; Fackler OT Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210 [TBL] [Abstract][Full Text] [Related]
25. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression. Dotson D; Woodruff EA; Villalta F; Dong X J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839 [TBL] [Abstract][Full Text] [Related]
26. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106 [TBL] [Abstract][Full Text] [Related]
27. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. Kueck T; Neil SJ PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182 [TBL] [Abstract][Full Text] [Related]
29. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release. Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285 [TBL] [Abstract][Full Text] [Related]
30. Transmembrane interactions of HIV-1 Vpu and tetherin. Guo F; Liang C Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177 [TBL] [Abstract][Full Text] [Related]
31. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238 [TBL] [Abstract][Full Text] [Related]
32. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779 [TBL] [Abstract][Full Text] [Related]
33. Tetherin restricts direct cell-to-cell infection of HIV-1. Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674 [TBL] [Abstract][Full Text] [Related]
34. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718 [TBL] [Abstract][Full Text] [Related]
35. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933 [TBL] [Abstract][Full Text] [Related]
37. Tetherin/BST-2: Restriction Factor or Immunomodulator? Li SX; Barrett BS; Guo K; Santiago ML Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 Vpu and BST-2/tetherin: enemies at the gates. Tokunaga K Curr HIV Res; 2012 Jun; 10(4):275-6. PubMed ID: 22533470 [No Abstract] [Full Text] [Related]
39. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA. Lv M; Zhu Y; Wang J; Zhang H; Wang X; Zuo T; Liu D; Zhang J; Wu J; Kong W; Yu X Protein Expr Purif; 2013 Oct; 91(2):112-8. PubMed ID: 23916489 [TBL] [Abstract][Full Text] [Related]
40. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Sauter D; Schindler M; Specht A; Landford WN; Münch J; Kim KA; Votteler J; Schubert U; Bibollet-Ruche F; Keele BF; Takehisa J; Ogando Y; Ochsenbauer C; Kappes JC; Ayouba A; Peeters M; Learn GH; Shaw G; Sharp PM; Bieniasz P; Hahn BH; Hatziioannou T; Kirchhoff F Cell Host Microbe; 2009 Nov; 6(5):409-21. PubMed ID: 19917496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]